3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Cyclophosphamide
69
fludarabine phosphate
63
Busulfan
45
Peripheral Blood Stem Cell Transplantation
42
Tacrolimus
40
Mycophenolic Acid
37
Filgrastim
35
Antilymphocyte Serum
35
fludarabine
31
Cyclosporine
30
Radiotherapy
29
Melphalan
29
Whole-Body Irradiation
27
Methotrexate
24
Etoposide
20
Cord Blood Stem Cell Transplantation
18
Biopsy
18
Methylprednisolone
16
Specimen Handling
15
Rituximab
14
Magnetic Resonance Spectroscopy
13
Alemtuzumab
12
Stem Cell Transplantation
11
Granulocyte Colony-Stimulating Factor
11
Cytarabine
11
sargramostim
9
Sirolimus
9
Prednisone
9
Dexamethasone
9
plerixafor
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
ficlatuzumab
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled